Right ventricular lead sensing latency in pacemaker therapy

Fani Zagkli, Nikoleta Kalovrenti, Panagiotis Patrinos, Panagiotis Chronopoulos, John ChiladakisJournal of Arrhythmia 2022 · DOI

TL;DR

This study quantifies the delay between the heart's electrical signal (QRS) and when a pacemaker lead actually "sees" it (sensing latency). They found this delay is longer than expected, especially in patients with certain heart conditions (RBBB) and with specific pacemaker brands, highlighting the need for personalized pacemaker programming to avoid unnecessary pacing.

What Problem Does This Paper Address?

Pacemakers are designed to sense the heart's natural electrical activity and only intervene when necessary. This sensing relies on a right ventricular (RV) lead picking up the local electrogram (EGM). A critical step during pacemaker implantation is intraoperative testing using a pacing system analyzer (PSA) to ensure the lead can reliably detect the heart's signal. The assumption is that the PSA's readings accurately reflect how the implanted pacemaker will perform. However, there's a known phenomenon of signal propagation and processing delays between the actual electrical event in the heart and its detection by the lead and subsequent processing by the device. This "sensing latency" can be problematic, potentially leading to the pacemaker missing intrinsic beats and delivering unnecessary pacing, especially in patients with underlying conduction abnormalities. This paper aims to precisely quantify this RV lead sensing latency and explore factors that influence it, such as the testing method (PSA vs. implanted pacemaker), patient characteristics (QRS duration), and pacemaker manufacturer.

Methods

The researchers conducted a study involving 157 patients undergoing dual-chamber pacemaker implantation. These patients had no significant heart disease and maintained intrinsic atrioventricular (AV) conduction. The RV lead was positioned on the mid-septum.

The core of their methodology involved measuring the Q-VS interval, which represents the sensing latency. This is defined as the time difference between the onset of the QRS complex on a surface electrocardiogram (ECG) and the sensed ventricular electrogram (VS) event marker detected by the RV lead.

Measurements were taken in two scenarios:

  1. Intraoperatively using a Pacing System Analyzer (PSA): Real-time sensing data was captured via the PSA unit connected to the implanted lead.
  2. Post-implantation using the Pacemaker: After the pacemaker was implanted, the same sensing latency was measured using the device's own telemetry and programmer.

Patients were categorized into two groups based on their baseline QRS duration: narrow QRS (<120ms) and wide QRS (≥120ms), specifically those with complete right bundle branch block (RBBB). The study also compared data between Medtronic and Abbott pacemaker systems.

Datasets

Not discussed in the paper. The study utilized data collected directly from the 157 participating patients during their pacemaker implantation procedures.

Key Insights and Ideas

  • The "Invisible" Delay: The most significant insight is that there's a measurable and often substantial delay between the heart's electrical signal (QRS) and when the pacemaker lead actually registers it. This delay, the sensing latency, is not negligible and has practical implications.
  • PSA vs. Pacemaker: A Discrepancy: The study revealed that intraoperative testing with a PSA consistently shows longer sensing latency compared to the implanted pacemaker. This challenges the assumption that PSA readings are a perfect proxy for post-implant performance.
  • RBBB is a Key Factor: Patients with a wide QRS due to RBBB exhibit significantly longer sensing latency than those with a narrow QRS. This suggests that underlying conduction abnormalities directly impact how quickly the RV lead can reliably detect the heart's signal.
  • Manufacturer Differences Matter: There are notable differences in sensing latency between Medtronic and Abbott pacemakers, particularly in patients with narrow QRS. This points to variations in device design, sensing algorithms, or lead characteristics influencing performance.
  • Clinical Relevance for AV Delay: Understanding this sensing latency is crucial for optimizing AV delay programming. A longer AV delay might be necessary to accommodate this inherent latency, preventing unnecessary ventricular pacing and ensuring proper coordination between atrial and ventricular contractions.

Key Results

  • Overall Latency: All patients showed a greater mean Q-VS (sensing latency) through the PSA (56.5 ± 28.4 ms) compared to the implanted pacemaker (22.5 ± 14.8 ms) (p < 0.0001).
  • Narrow QRS vs. RBBB:
    • Narrow QRS patients: PSA latency was 50.9 ± 24.2 ms; pacemaker latency was 18.2 ± 12.8 ms.
  • RBBB patients: PSA latency was 67.8 ± 32.9 ms; pacemaker latency was 31.2 ± 14.8 ms.
  • RBBB patients consistently had longer sensing latency than narrow QRS patients, both through PSA and the pacemaker (p < 0.001).
  • Manufacturer Comparison (Narrow QRS): Medtronic pacemakers showed longer sensing latency than Abbott pacemakers (p < 0.05).
  • Manufacturer Comparison (RBBB): While Medtronic showed longer latency through PSA, the difference was not statistically significant through the pacemaker (p = 0.08).

Limitations and Future Work

  • RV Lead Placement: The study focused on RV lead placement in the mid-septum. The findings may not be directly applicable to other RV pacing sites.
  • Manufacturer Scope: The study included Medtronic and Abbott devices. Other pacemaker manufacturers might yield different results.
  • Patient Population: The study excluded patients with underlying cardiac disease. Future research could explore how these findings apply to more complex patient populations.
  • Future Directions: The authors suggest that individualized AV delay programming, potentially extending the AV delay to match the measured RV lead electrical delay, could help prevent unnecessary ventricular pacing, especially in patients with intrinsic RBBB. Further investigation into the specific design and engineering differences between manufacturers that contribute to these latency variations is also warranted.

Summary updated

Abstract

We demonstrated longer RV lead sensing latency (1) through PSA than through pacemaker, (2) in RBBB than in narrow-QRS, and (3) in Medtronic pacemakers compared with Abbott pacemakers. Knowledge of sensing latency helps the optimization of the AV delay.
BibTeX
@article{zagkli2022right,
  author = {Fani Zagkli and Nikoleta Kalovrenti and Panagiotis Patrinos and Panagiotis Chronopoulos and John Chiladakis},
  title = {{Right ventricular lead sensing latency in pacemaker therapy}},
  journal = {Journal of Arrhythmia},
  year = {2022},
  doi = {10.1002/joa3.12767},
}
Figure